International consensus statement on the use of disease-modifying agents in multiple sclerosis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: L773:1352 4585 OR L773:1477 0970 > (2000-2004) > International conse...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		02933naa a2200409 4500
001		oai:lup.lub.lu.se:c8b72c6a-03e5-4d43-82d3-d9915996a645
003		SwePub
008		160401s2002 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://lup.lub.lu.se/record/3422542 URI
024	7	a https://doi.org/10.1191/1352458502ms769oa2 DOI
040		a (SwePub)lu
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Freedman, MS4 aut
245	1 0	a International consensus statement on the use of disease-modifying agents in multiple sclerosis
264		c 2016-07-02
264	1	b SAGE Publications,c 2002
520		a Objective. To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods. An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment Results: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
653		a multiple sclerosis
653		a interferon beta
653		a consensus
653		a glatiramer acetate
700	1	a Blumhardt, LD4 aut
700	1	a Brochet, B4 aut
700	1	a Comi, G4 aut
700	1	a Noseworthy, JH4 aut
700	1	a Sandberg Wollheim, Magnhildu Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)neur-msw
700	1	a Sorensen, PS4 aut
710	2	a Neurologi, Lundb Sektion IV4 org
773	0	t Multiple Sclerosis Journald : SAGE Publicationsg 8:1, s. 19-23q 8:1<19-23x 1477-0970x 1352-4585
856	4	u http://dx.doi.org/10.1191/1352458502ms769oay FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/342254
856	4 8	u https://doi.org/10.1191/1352458502ms769oa

Hitta via bibliotek

Multiple Sclerosis Journal (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Freedman, MS; Blumhardt, LD; Brochet, B; Comi, G; Noseworthy, JH; Sandberg Wollhei ...; visa fler...; Sorensen, PS; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Artiklar i publikationen: Multiple Scleros ...

Av lärosätet: Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se